Floatz logo

Bgb-16673

Chronic Lymphocytic Leukemia

M.D. Anderson Cancer CenterPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
65/ 100

Competitive context

211 Active assets in the Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Weill Medical College of Cornell University
Phase 2BBB
Fludarabine
Roswell Park Cancer Institute
Phase 3BBB
Apg-2575
Henan Cancer Hospital
Phase 3BBB
CHLORAMBUCIL
Ascentage Pharma Group Inc.
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 4BBB

View all 50 →

Same molecule, other indications

Bgb-16673 is also rated in:

diffuse large B-cell lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
CC
Indicative ·
47 / 100
View asset →
B-cell neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →